US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS).
Abide has also partnered with the Tourette Association of America (TAA) to understand the unmet needs in the Tourette community.
ABX-1431 is an investigational, orally available, small-molecule monoacylglycerol lipase (MGLL) inhibitor.
The cross-over Phase 1b trial will evaluate the ability of ABX-1431 to modulate the endocannabinoid neurotransmitter system activity.
The trial aims to determine the effect of a highly specific endocannabinoid modulator when assessed under controlled conditions compared to established benefits of exocannabinoids.
Abide Therapeutics president and chief executive officer Alan Ezekowitz said: "We are excited to begin this trial in adults with Tourette Syndrome, and we hope to subsequently extend our studies to children, since Tourette Syndrome is largely considered to be a disease of childhood.
"As we continue to explore the potential utility of ABX-1431 in Tourette Syndrome, we are grateful for the opportunity to partner with the TAA to further understand the challenges faced by those affected by the condition."
Following the completion of dosing in the Phase Ia trial, ABX-1431 was found to be well tolerated without any serious adverse events.
According to the preliminary data from a PET occupancy study, ABX-1431 showed dose-dependent brain penetrance via Abide's MGLL-specific PET ligand known as [18F]ABX-1488.
Additionally, the firm is planning to begin dosing patients in a fMRI trial investigating ABX-1431-related neural activity patterns in the brain.